Founded in 1992, Conceptus (NASDAQ: CPTS) is dedicated to the revolutionary design, development, and marketing of innovative solutions in women's health. Conceptus is also a leader in anticipating and addressing the needs of the U.S. healthcare market.

The Company's flagship product, the Essure procedure, was the first-ever successful, non-surgical permanent birth control procedure approved for use in the U.S and Europe, and is the most effective method of permanent birth control available. The Essure procedure is performed using a hysteroscope in less than 10 minutes, typically in a physician's office, and is less invasive and less expensive than tubal ligation surgery. Essure has been on the market in the U.S. since 2002 and more than 550,000 Essure procedures have been performed worldwide. As the pioneer of hysteroscopic sterilization, the Company is committed to establishing Essure as the "standard of care" in permanent birth control.